表紙
市場調査レポート

Symbicort(ぜんそく):市場の予測と分析

Symbicort (Asthma) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 316074
出版日 ページ情報 英文 52 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
Symbicort(ぜんそく):市場の予測と分析 Symbicort (Asthma) - Forecast and Market Analysis to 2023
出版日: 2014年08月31日 ページ情報: 英文 52 Pages
概要

SymbicortはAstraZenecaが開発した、ブデソニドとフマル酸フォルモテロールのFDC(多剤混合薬)です。ブデソニドは強力な消炎作用のある合成コルチコステロイド剤で、 グルココルチコイド受容体と高い親和性で結合し、ぜんそく媒介物質の分泌を阻害する働きをします。ブデソニドはAstraZenecaより、Symbicortという独立型製品として上市されています。フマル酸フォルモテロールは高度に選択的なLABA(長時間作用性β2刺激薬)であり、cAMPを増加させ、更には気管支平滑筋の緊張緩和をもたらす効果があります。

当レポートでは、ぜんそくの治療薬の一つ、Symbicortの世界市場について分析し、ぜんそくの概要や治療法、競合する企業・薬品の概要、市場競争の概況、Symbicortの商品情報(特色・効能・安全性など)、世界の主要国における市場販売額の見通し(今後10年間分)などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 分析の背景事情
  • 関連報告
  • 公開予定の関連報告書

第3章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
    • 予後
    • 生活の質(QoL)
  • 症状

第4章 疾患管理

  • 診断および治療の概要
    • 診断
    • 治療ガイドライン、臨床診療および代表的な処方薬
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合評価

第6章 Symbicort(ブデソニド/フマル酸フォルモテロール)

  • 概要
  • 有効性
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表一覧

目次

GlobalData has released its new PharmaPoint Drug Evaluation report, "Symbicort (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Symbicort is an FDC of budenoside and formoterol fumarate developed by AstraZeneca. Budesonide is a synthetic corticosteroid with strong anti-inflammatory activity. It can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma. Budesonide is marketed by AstraZeneca as a standalone product called Symbicort. Formoterol fumarate is a highly selective LABA. It acts by increasing cAMP, which, in turn, leads to relaxation of the bronchial smooth muscle.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Symbicort including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Symbicort for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Symbicort performance
  • Obtain sales forecast for Symbicort from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Symbicort (budenoside/formoterol fumarate)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Asthma Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Author/Reviewer
    • 7.6.3. Reviewer
    • 7.6.4. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Product Profile - Symbicort
  • Table 8: Efficacy - Symbicort Versus Its Individual Components
  • Table 9: Symbicort, Frequency of Drug-Related Adverse Events
  • Table 10: Symbicort SWOT Analysis, 2014
  • Table 11: Global Sales Forecast ($) for Symbicort, 2013-2023
  • Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Back to Top